Several other research analysts also recently commented on MLAB. Zacks Investment Research downgraded Mesa Laboratories from a hold rating to a strong sell rating in a research note on Wednesday. TheStreet raised Mesa Laboratories from a c+ rating to a b rating in a research note on Tuesday, July 30th. ValuEngine raised Mesa Laboratories from a sell rating to a hold rating in a research note on Friday, November 1st. Finally, Evercore ISI began coverage on Mesa Laboratories in a research note on Monday, August 26th. They issued an outperform rating and a $250.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. Mesa Laboratories currently has a consensus rating of Hold and a consensus price target of $247.00.
Shares of NASDAQ MLAB traded down $2.25 during trading on Wednesday, reaching $237.59. The company had a trading volume of 40,700 shares, compared to its average volume of 58,437. The business’s 50-day moving average is $228.54 and its 200 day moving average is $231.25. The company has a quick ratio of 1.26, a current ratio of 1.59 and a debt-to-equity ratio of 0.15. Mesa Laboratories has a 12-month low of $181.21 and a 12-month high of $268.47. The stock has a market cap of $1.05 billion, a PE ratio of 44.24 and a beta of 0.18.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 29th will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Wednesday, November 27th. Mesa Laboratories’s dividend payout ratio (DPR) is currently 11.92%.
Hedge funds and other institutional investors have recently bought and sold shares of the company. NEXT Financial Group Inc raised its stake in shares of Mesa Laboratories by 789.6% in the second quarter. NEXT Financial Group Inc now owns 1,281 shares of the medical instruments supplier’s stock worth $313,000 after buying an additional 1,137 shares during the period. Kistler Tiffany Companies LLC raised its stake in Mesa Laboratories by 2,072.7% during the 2nd quarter. Kistler Tiffany Companies LLC now owns 29,440 shares of the medical instruments supplier’s stock valued at $7,193,000 after purchasing an additional 28,085 shares during the period. Arizona State Retirement System bought a new stake in Mesa Laboratories during the 2nd quarter valued at approximately $1,344,000. Comerica Bank raised its stake in Mesa Laboratories by 97.3% during the 3rd quarter. Comerica Bank now owns 20,424 shares of the medical instruments supplier’s stock valued at $4,546,000 after purchasing an additional 10,071 shares during the period. Finally, Yorktown Management & Research Co Inc raised its stake in Mesa Laboratories by 20.3% during the 2nd quarter. Yorktown Management & Research Co Inc now owns 5,000 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 843 shares during the period. 81.12% of the stock is currently owned by hedge funds and other institutional investors.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.